GlobeNewswire by notified

Ensurge Micropower ASA - Disclosure of Large Shareholdings

Share

This disclosure is sent on behalf of certain large shareholders in Ensurge Micropower ASA (the "Company").

Reference is made to the announcement by the Company on 14 March 2023 regarding the approval of the Private Placement of 500,000,000 new shares by the Extraordinary General Meeting. Favuseal AS and Schlytter-Henrichsen AS have been allocated new shares in the Private Placement. Amandator AS, close associate of Favuseal AS and Schlytter-Henrichsen AS, discloses the following information pursuant to Section 4-2 of the Norwegian Securities Trading Act and the Securities Trading Act Regulations.

On a consolidated basis, Amandator AS will be issued 40,000,000 shares in the Private Placement. Upon registration of the Private Placement in the Norwegian Register of Business Enterprises and subsequent delivery of shares, the consolidated shareholding of Amandator AS will represent 5.65% of the Company's total number of outstanding shares, holding the number of shares stated below:  

 Legal entity Number of shares % shares/votes 
Favuseal AS21,631,7222.91%
Schlytter-Henrichsen AS20,426,2742.74%

The disclosure obligation is triggered by Amandator AS crossing above the 5% threshold of total number of voting rights and shares in Ensurge Micropower ASA.

15 March 2023

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

EgnsINVEST Ejendomme Tyskland A/S - Samlet driftsresultat (EBVAT) i 2022 – 27,1 mio. kr.23.3.2023 13:10:20 CET | pressemeddelelse

Den 23. marts 2023 Samlet resultat før skat i 2022, 15,6 mio. kr.Kreditfaciliteter til rådighed for 35,8 mio. kr.Negativ værdiregulering på 0,68% af investeringsejendommenes dagsværdi (-11,5 mio. kr.) EgnsINVEST Ejendomme Tyskland A/S har realiseret et resultat før skat i 2022 på i alt 15,6, mio. kr. på koncernniveau mod 147,4 mio. kr. sidste år, hvilket ledelsen betragter som tilfredsstillende, da driften af koncernens ejendomme er forbedret siden sidste år. Af årets resultat udgør værdiregulering af investeringsejendommene -11,5 mio. kr. mod 121,1 mio. kr. sidste år. Driftsresultatet (EBVAT) er dermed på 27,1 mio. kr. mod 26,2 mio. kr. sidste år. Årets driftsresultat indfrier de opjusterede forventninger om, at årets EBVAT ville ligge i intervallet 26,8-27,1 mio. kr., hvilket blev meldt ud i den seneste periodemeddelelse. Der er i løbet af året foretaget en tilbageførsel af afsatte hensættelser til tab på erhvervslejere relateret til covid-19. Erhvervslejerne fik under pandemien i 20

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients23.3.2023 12:55:29 CET | Press release

Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy COPENHAGEN, Denmark, March 23, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies today announces that it has developed a new proprietary AI platform technology ObsERV™ to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy. ObsERV™, Evaxion’s new proprietary AI platform technology, identifies patient-specific virus targets, so-called ERVs (endogenous retroviruses), expressed in cancer. Evaxion has demonstrated that overexpression of such ERVs is strongly associated with the overall survival of cancer patients,

Auctions of mortgage covered bonds for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3®23.3.2023 12:49:47 CET | Press release

To Nasdaq Copenhagen A/S Executive Board Lersø Parkalle 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 23 March 2023 Company Announcement number 22/2023 Auctions of mortgage covered bonds for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3® Realkredit Danmark will hold auctions on SDRO’s for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3® as of 1 July 2023. The auctions will be held on 24 - 25 May 2023. Realkredit Danmark will open two new mortgage covered bonds (SDRO’s) to put on the auctions for the refinancing of RD Cibor6® and RD Euribor3®, respectively. The underlying bond to RD Cibor6® will be used for new loan offers at a later stage whereas the underlying bond to RD Euribor3® will be used for new loan offers immediately after the refinancing has taken place. At the auctions, investors make their bids on the spread to CIBOR 6M and EURIBOR 3M. Regarding FlexKort®, investors make their bids on the price of DK0004626322. The characteristics of the new

Auktioner over obligationer til refinansiering af FlexKort®, RD Cibor6® og RD Euribor3®23.3.2023 12:49:47 CET | pressemeddelelse

Til Nasdaq Copenhagen A/S Direktionen Lersø Parkalle 100 2100 København Ø www.rd.dk Telefon 7012 5300 23. marts 2023 Selskabsmeddelelse nummer 22/2023 Auktioner over obligationer til refinansiering af FlexKort®, RD Cibor6® og RD Euribor3® Realkredit Danmark gennemfører auktioner over SDRO til refinansiering af FlexKort®, RD Cibor6® og RD Euribor3® pr. 1. juli 2023. Auktionerne vil blive afholdt den 24. og 25. maj 2023. Til brug for auktionerne åbner Realkredit Danmark to nye obligationer til refinansiering af henholdsvis RD Cibor6® og RD Euribor3®. Obligationen bag RD Cibor6® vil på sigt blive anvendt til lånetilbud mens obligationen bag RD Euribor3® vil blive anvendt til lånetilbud umiddelbart efter refinansieringen. På auktionen skal investorer byde på tillægget til CIBOR 6M og EURIBOR 3M, mens der på auktionen vedrørende FlexKort® skal bydes på kursen til DK0004626322. De nye obligationers karakteristika fremgår af vedlagte bilag. De Endelige vilkår offentliggøres via prospektmeddel

Fixing of coupon rates - Nykredit Realkredit A/S23.3.2023 12:34:03 CET | Press release

To Nasdaq Copenhagen FIXING OF COUPON RATES 23 March 2023 Fixing of coupon rates effective from 27 March 2023 Effective from 27 March 2023, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S will be adjusted. Bonds with quarterly interest rate fixing The new coupon rates will apply from 27 March 2023 to 27 June 2023: Uncapped bonds DK0030486246, (SNP), maturity in 2024, new rate as at 27 March 2023: 3.9900% pa DK0030492053, (SNP), maturity in 2023, new rate as at 27 March 2023: 3.9900% pa DK0030494851, (SNP), maturity in 2023, new rate as at 27 March 2023: 3.7400% pa Questions may be directed toInvestor Relations at investor_relations@nykredit.dkor Rikke Gredsted Seidenfaden, Head of Press Relations,tel +45 44 55 14 49. Attachment Fixing of coupon rates - Nykredit Realkredit - 20230323